Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2025-10-02
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 60
- Registration Number
- NCT05780034
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸Colorado Blood Cancer Institute, Denver, Colorado, United States
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 8
- Registration Number
- NCT05673109
- Locations
- 🇨🇳
Site 2001, Beijing, China
🇨🇳Site 2003, Guangzhou, China
🇨🇳Site 2004, Hunan, China
Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-09-30
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 100
- Registration Number
- NCT05654532
- Locations
- 🇺🇸
Site 08, Denver, Colorado, United States
🇺🇸Site 07, Orlando, Florida, United States
🇺🇸Site 06, Rockville, Maryland, United States
A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 6
- Registration Number
- NCT05489679
- Locations
- 🇨🇳
Site 1001, Beijing, China
🇨🇳Site 1003, Hangzhou, China
🇨🇳Site 1002, Tianjin, China
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Accutar Biotechnology Inc
- Target Recruit Count
- 28
- Registration Number
- NCT05241613
- Locations
- 🇺🇸
Site 02, Denver, Colorado, United States
🇺🇸Site 03, Sarasota, Florida, United States
🇺🇸Site 05, Detroit, Michigan, United States
- Prev
- 1
- 2
- Next